Assessing tissue cross-reactivity (TCR) is key to helping minimize risk of harm in first-in-human studies for therapeutic antibodies and antibody-like molecules. This insightful paper shares critical considerations to ensure your TCR study generates the requisite robust data to support pre-clinical decision-making and regulatory submissions.